Ceftazidim Hospira 1 g prašek za raztopino za injiciranje/infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceftazidim hospira 1 g prašek za raztopino za injiciranje/infundiranje

hospira uk ltd - ceftazidim - prašek za raztopino za injiciranje/infundiranje - ceftazidim 1000 mg / 1 viala - ceftazidim

Ceftazidim Hospira 2 g prašek za raztopino za injiciranje/infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ceftazidim hospira 2 g prašek za raztopino za injiciranje/infundiranje

hospira uk ltd - ceftazidim - prašek za raztopino za injiciranje/infundiranje - ceftazidim 2000 mg / 1 viala - ceftazidim

Soludeks 100 mg/ml raztopina za infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

soludeks 100 mg/ml raztopina za infundiranje

hrvatski zavod za transfuzijsku medicinu - dekstran; natrijev klorid - raztopina za infundiranje - dekstran 100 g / 1000 ml  natrijev klorid9 g / 1000 ml; natrijev klorid 9 g / 1000 ml - dekstran

FELOCELL CVR Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

felocell cvr

iris -

Norcuron 4 mg prašek za raztopino za injiciranje ali infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

norcuron 4 mg prašek za raztopino za injiciranje ali infundiranje

n. v. organon, oss - vekuronijev bromid - prašek za raztopino za injiciranje/infundiranje - vekuronijev bromid 4 mg / 1 ampula - vekuronium

Norcuron 4 mg prašek in vehikel za raztopino za injiciranje ali infundiranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

norcuron 4 mg prašek in vehikel za raztopino za injiciranje ali infundiranje

n. v. organon, oss - vekuronijev bromid - prašek in vehikel za raztopino za injiciranje/infundiranje - vekuronijev bromid 4 mg / 1 ampula - vekuronium

Purevax RCCh Evropska unija - slovenščina - EMA (European Medicines Agency)

purevax rcch

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. na imunski sistem je bil dokazan 1 teden po osnovnem cepljenju za rinotraheitis, kalicivirus in komponento chlamydophila felis. trajanje imunosti je 1 leto po zadnjem (ponovnem) cepljenju.

Purevax RCP Evropska unija - slovenščina - EMA (European Medicines Agency)

purevax rcp

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Purevax RCP FeLV Evropska unija - slovenščina - EMA (European Medicines Agency)

purevax rcp felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCPCh Evropska unija - slovenščina - EMA (European Medicines Agency)

purevax rcpch

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals za skupin felidae, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. nastopi imunosti so dokazali en teden po primarno cepljenje seveda za rhinotracheitis, calicivirus, chlamydophila felis in panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.